A new antibody-drug conjugate (ADC) has received US approval to treat patients with a type of non-Hodgkin lymphoma after showing an overall response rate of 48.3% in a pivotal Phase 2 trial. Zynlonta (loncastuximab tesirine) was authorised by the Food and Drug Administration as a single-agent treatment for diffuse large B cell lymphoma (DLBCL) – the first single-agent ADC for this disease. Patients in the trial had already received two or more lines of systemic therapy, but these treatments had failed.
